Tevogen Bio, a clinical stage biotechnology company, has submitted its Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for the development of COVID-19 treatment using proprietary antigen specific T cell technology, it was reported on Wednesday.
The company is collaborating with bone marrow transplant expert, Dr Neal Flomenberg, chair of the Department of Medical Oncology at Thomas Jefferson University, with the aim of assessing the company's T cell technology to treat hospitalised COVID-19 patients.
The partnership intends to use Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in research and the transplantation of T cells so that both can conduct clinical trials of T cell treatments for COVID-19. In the proposed trials, T cells will be generated in the laboratory and administered to those patients in the COVID-19 spectrum that are most ill.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories